Company Overview
Aces Diagnostics was founded with a simple goal: to give physicians better tools to diagnose Lyme disease earlier and more accurately.
Driven by both scientific expertise and personal experience, our team includes leaders in Lyme disease research, diagnostics, bioinformatics, regulatory affairs, and commercialization. Together, we are working to address one of the most persistent challenges in medicine—accurate Lyme disease diagnosis.
Our flagship technology, LYMESEEK™, has demonstrated greater than 90% accuracy across all stages of Lyme disease and is designed to help clinicians identify infection sooner than current testing approaches.
We believe earlier answers lead to earlier treatment, better outcomes, and fewer patients left searching for a diagnosis.
Our Personal Story
Aces Diagnostics was born from a shared experience no parent should have to face.
After watching their daughters struggle for years with debilitating symptoms caused by Lyme disease, our founders experienced firsthand the consequences of delayed and inaccurate diagnosis. What began as a search for answers became a mission to improve the future for Lyme disease patients everywhere.
Founded in 2024, after 9 years of research, Aces Diagnostics is committed to developing innovative diagnostic solutions that help physicians identify Lyme disease earlier, enabling faster treatment and better outcomes for patients.
Team
Dedication. Expertise. Passion.
The team behind LymeSeek combines expertise in diagnostics, Lyme disease research, regulatory strategy, commercialization, and artificial intelligence. Together, our leadership team has decades of experience bringing innovative healthcare technologies from development through market adoption.
.png)
Founder & Chief Executive Officer
Tammy Crawford
Entrepreneur, healthcare executive, and Lyme disease advocate with a successful prior exit. Tammy founded Aces Diagnostics after witnessing firsthand the devastating impact of delayed Lyme disease diagnosis. She leads corporate strategy, fundraising, partnerships, and commercialization efforts for LymeSeek.
Key focus: Business strategy, partnerships, fundraising, commercialization
Founder & Chief Scientific Officer
Holly Ahern, MS, MT(ASCP)
Microbiologist, educator, and nationally recognized Lyme disease expert with more than two decades of experience in infectious disease. Holly oversees scientific strategy and clinical evidence generation and is a leading voice in Lyme disease awareness and research.
Key focus: Scientific leadership, clinical evidence, Lyme disease expertise
Founder & Chief Research Officer
Monica Embers, PhD
Professor and internationally recognized Lyme disease researcher whose work has advanced understanding of Borrelia infection and immune response. Dr. Embers guides translational research and clinical validation efforts supporting LymeSeek.
Key focus: Research, biomarker discovery, clinical validation
Founder & Chief Business Officer
Todd Snowden
Former diagnostics CEO with experience building and exiting a diagnostics company. Todd leads commercialization strategy, business development, market access, and partnerships across U.S. and European markets.
Key focus: Commercialization, strategic partnerships, market expansion
.png)
Chief Development Officer
Jim Kirk, PhD
Diagnostics development executive with extensive experience bringing regulated healthcare products from concept through manufacturing and commercialization.
Key focus: Product development, manufacturing readiness, regulatory execution
Chief Financial Officer
Lisa Stone
Finance and operations executive with experience supporting growth-stage healthcare companies through fundraising, strategic planning, and corporate development.
Key focus: Finance, investor relations, corporate strategy
Chief Data Officer
Phillip Stafford, PhD
Bioinformatics and machine learning expert with extensive experience applying advanced analytics to complex biological datasets. Dr. Stafford leads development of the proprietary LymeSeek algorithm.
Key focus: Artificial intelligence, machine learning, biomarker analytics
Director of Development
Cindy Jones
Development professional with experience in fundraising, investor engagement, and strategic communications. Cindy leads investor relations, partnership development, and stakeholder outreach initiatives that support the growth and commercialization of LYMESEEK™.
Key Focus: Fundraising, Investor Relations, Business Development, Communications
Capital Development Liaison
Ann Desotelle
Healthcare professional and Lyme disease advocate with extensive experience building relationships within the Lyme disease community. Ann supports fundraising efforts, using skills from business ownership, by connecting the company with investors and strategic stakeholders who share the mission of improving Lyme disease diagnosis.
Key Focus: Capital Development, Investor Introductions, Stakeholder Engagement
Scientific & Strategic Advisors
Our advisors bring expertise spanning infectious disease, diagnostics, commercialization, reimbursement, and healthcare innovation.
John McDonough
John is currently the CEO and Board chairman at Sunbird Bio, and also serves as chairman at Cytrellis Biosystems. With experience spanning more than 30 years, John has raised more than $500 million in public and private capital, creating over $6 billion of market value for five different companies.
.jpg)
Brian Fallon, MD MPH
Brian heads the national TBD Clinical Trials Network and Director of the Lyme and Tick-Borne Diseases Research Center at Columbia University. He is also recognized internationally for his research on neurologic and neuropsychiatric Lyme disease and is the director of the Center for Neuroinflammatory Disorders and Biobehavioral Medicine.
.jpg)
Mark Soloski
Mark is an Emeritus Professor at Johns Hopkins University School of Medicine and the Senior Advisor for the Johns Hopkins Lyme Disease Research Center. As a leading researcher in the area of Lyme disease, Mark studies the role that infection plays in setting the stage for chronic immune-mediated inflammatory diseases, including Lyme disease.
Michael Saubolle, PhD
Michael is the Emeritus Medical Director, Infectious Diseases Division, Sonora Quest Laboratories, a joint venture between Banner Health and Quest Diagnostics. Sonora Quest Laboratories is the market share leader in clinical laboratory testing in Arizona, performing more than 60 million diagnostic tests per year.
Glenn de Souza
Glenn is the Founder and Chief Executive Officer at The Unispec Companies, a holding and development company that has originated and managed more than $50M in healthcare and commercial real estate, projects. Under his direction, Unispec conceived, licensed, and operated multiple long-term acute-care hospitals and rehabilitation centers.
Ninon Tantet
Ninon is the President of the Bill and Marian Cook Foundation, her family’s private foundation dedicated to advancing wellness, medical research, women’s issues, and land stewardship in the American West.
